December 2024 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows promise by targeting androgen receptors.
August 2002 in “Inpharma Weekly” 8 citations
,
June 2023 in “European Journal of Endocrinology” The inhibitor affects androgen metabolism but not ovarian function.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
4 citations
,
December 2012 in “PubMed” January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
July 2025 in “International Journal of Biological Macromolecules” The microneedle patch boosts hair growth by reducing DHT and oxidative stress.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
March 2005 in “European Urology Supplements” 1 citations
,
April 2015 in “The FASEB journal” UVB exposure increases skin proteins for retinoic acid synthesis and shifts their location, possibly affecting skin repair.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
September 2023 in “Journal of the American Academy of Dermatology”
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
July 2025 in “Journal of Investigative Dermatology” 5% ET-02 is a more effective and safe treatment for hair loss than current options.
January 2025 in “Archives of Dermatological Research”
January 2023 in “Journal of cosmetic dermatology” The synthetic retinoid EC23 thickens skin and promotes hair growth more effectively and with a lower dose than natural retinoids.
December 2012 in “http://isrctn.org/>” October 2009 in “Nature Reviews Urology” March 2026 in “Mendeley Data” January 2026 in “Mendeley Data” March 2026 in “Mendeley Data” 34 citations
,
September 1997 in “Acta Dermato Venereologica” RXR agonists may promote hair growth in humans.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.